US20020045611A1 - Pharmaceutical compositions comprising metal complexes - Google Patents

Pharmaceutical compositions comprising metal complexes Download PDF

Info

Publication number
US20020045611A1
US20020045611A1 US09/802,523 US80252301A US2002045611A1 US 20020045611 A1 US20020045611 A1 US 20020045611A1 US 80252301 A US80252301 A US 80252301A US 2002045611 A1 US2002045611 A1 US 2002045611A1
Authority
US
United States
Prior art keywords
formula
complex
disease
medicament
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US09/802,523
Other versions
US6417182B1 (en
Inventor
Michael Abrams
Simon Fricker
Barry Murrer
Owen Vaughan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939317686A external-priority patent/GB9317686D0/en
Priority claimed from US09/175,028 external-priority patent/US6284752B1/en
Application filed by Individual filed Critical Individual
Priority to US09/802,523 priority Critical patent/US6417182B1/en
Priority to US10/017,764 priority patent/US20020193363A1/en
Publication of US20020045611A1 publication Critical patent/US20020045611A1/en
Application granted granted Critical
Publication of US6417182B1 publication Critical patent/US6417182B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Definitions

  • This invention relates to new pharmaceutical compositions and to pharmaceutical compositions having activity against diseases caused by or related to overproduction or localised high concentration of nitric oxide in the body.
  • Nitric oxide plays a varied and vital role in the human body.
  • NO plays a vital role in the control of blood pressure; it acts as a neurotransmitter; it plays a role in inhibition of platelet aggregation (important in thrombosis or blockages of the blood vessels), and in cytostasis (important in fighting of tumours).
  • vascular/pressor diseases such as septic shock, post-ischaemic cerebral damage, migraine, and dialysis induced renal hypotension
  • immunopathologic diseases such as hepatic damage in inflammation and sepsis, allograft rejection, graft versus host diseases, diabetes and wound healing
  • neurodegenerative diseases such as cerebral ischaemia, trauma, chronic epilepsy, Alzheimer's disease, Huntington's disease, and AIDS dementia complex
  • side effects of treatment such as restenosis following angioplastic treatment and secondary hypotension following cytokine therapy.
  • septic shock This is precipitated by local septicaemia or endotoxaemia, (high local levels of bacterial endotoxins).
  • the result is activation of macrophages, lymphocytes, endothelial cells and other cell types capable of producing NO, further mediated by cytokine production by these cells.
  • the activated macrophages produce excess NO which causes vasodilation of the blood vessels, and results in local vascular damage and vascular collapse. This destruction of vascular integrity may be so great that it leads to the collapse of haemodynamic homeostasis, the end result being death.
  • N G -monomethy-L-arginine L-NMMA
  • L-NMMA N G -monomethy-L-arginine
  • An aim of the present invention is to provide new and previously indicated pharmaceutical compositions which are able to modulate NO levels in the body by scavenging, or removing, NO in situ so that necessary NO synthesis continues while dangerous excesses are removed.
  • Some metal complexes are known in pharmaceutical compositions for the treatment of diseases of the human body. For example, certain complexes of platinum and ruthenium have been used or indicated in the treatment of cancer. Metal complexes have not however been previously indicated in the treatment of NO overproduction related diseases.
  • This invention provides for the use of a neutral, anionic or cationic metal complex having at least one site for coordination with NO, of formula
  • M is a metal ion or a mixture of metal ions
  • X is a cation or a mixture of cations
  • L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic Table;
  • Y is a ligand, or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom, which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table;
  • Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions
  • complex in this specification is meant a neutral complex or anionic or cationic species.
  • Group which is used herein is to be understood as a vertical column of the periodic table in which elements of each Group have similar physical and chemical properties.
  • the definition of the Periodic Table is that credited to Mendeleev; Chambers Dictionary of Science and Technology, 1974. Published by W & R Chambers Ltd.
  • This invention may also be stated as providing a method of attenuation of NO levels where NO is implicated in diseases of the human body, comprising administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of formula I.
  • This invention may also provide for the use of a neutral, anionic or cationic metal complex of formula I in the manufacture of a medicament for the treatment of NO overproduction related disease.
  • This invention may also be stated as providing a method of treatment of diseases of the human body resultant of overproduction of NO in the human body, comprising administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of formula I.
  • formula I represents an anionic species
  • a cation will also be present.
  • formula I represents a cationic species
  • an anion will also be present.
  • the metal complexes may be hydrated.
  • M is a first, second or third row transition metal ion.
  • M may be an Rh, Ru, Os, Mn, Co, Cr or Re ion, and is preferably an Rh, Ru or Os ion.
  • M is in an oxidation state III.
  • the metal ion for example ruthenium is in oxidation state III, the rate at which it binds with NO is significantly faster than when it is in oxidation state II.
  • X may be any cation, such as a mono-, di- or tri-valent cation. Suitable cations may be H + , K + , Na + , NH 4 + or Ca 2+ . Conveniently X may be H + , K + or Na + .
  • L is a ligand containing both nitrogen and oxygen donor atoms.
  • suitable such ligands include ethylenediamine -N,N′-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetriaminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta), dithioethanebis(ethylenenitrilo) tetraacetic acid (dtedta) anid N-(2-hydroxyethyl)ethylenediamine-triacetic acid (hedtra).
  • Y is a ligand containing nitrogen, oxygen, sulphur, carbon, or phosphorus donor groups.
  • nitrogen donor groups may be for example ammine, amine, nitrile and nitride or derivations thereof.
  • Suitable oxygen donor groups may be for example carboxylic acid, ester or derivations thereof, water, oxide, sulphoxide, hydroxide, acetate, lactate, propionate, oxalate and maltolate.
  • Suitable sulphur donor groups may be for example sulphoxide, dialkylsulphide, dithiocarbarnate or dithiophosphate.
  • Suitable carbon donor groups may be for example carbon monoxide or isocyanide.
  • Suitable phosphorus donor groups may be for example triallylphosphine.
  • Z may be any halide and is preferably chloride, bromide or iodide. Most conveniently, Z is chloride.
  • metal complexes for use according to the present invention include optionally hydrated ruthenium complexes of formula
  • L′′ is an amide or ester or derivative thereof, or a polydentate aminocarboxylate ligand, for example edta, nta, dipic, pic, edda, tropolone, dtpa, hedtra, tedta or dtedta or diamide of edta or dtpa or a mixture of any of these, and Y is as defined above and may for example be selected from acetylacetone (acac), a ⁇ -diketonate, water, dimethylsulphoxide (dmso), carboxylate, bidentate carboxylate, catechol, kojic acid, maltol, hydroxide, tropolone, malonic acid, oxalic acid, 2,3-dihydroxynaphthalene, squaric acid, acetate, a sulphate and a glycolate.
  • acac acetylacetone
  • dmso dimethylsulphoxide
  • metal complexes for use according to the present invention include optionally hydrated complexes of formula III
  • Y is a sulphur donor ligand.
  • such complex is present in
  • metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of formula
  • M′′′ is ruthenium and Y′′′ is an oxygen-donor ligand such as acetate, lactate, water, oxide, propionate (COEt), oxalate (ox), or maltolate (maltol) or a combination of these.
  • oxygen-donor ligand such as acetate, lactate, water, oxide, propionate (COEt), oxalate (ox), or maltolate (maltol) or a combination of these.
  • COEt propionate
  • oxalate ox
  • maltolate maltol
  • the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of formula III wherein M′′′ is ruthenium and Y′′′ is an oxygen-donor ligand selected from the group acetate, lactate, oxide, propionate and maltolate.
  • metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of formula
  • Y IV is a nitrogen-donor ligand such as ammine, ethylenediamine (en), pyridine (py), 1,10-phenanthroline (phen), 2,2-bipyridine (bipy) or 1,4,8,11-tetra-azacyclotetradecane (cyclam), 2,3,7,8,12,13,17,18-octaethylporphyrin (oep) or a combination of these.
  • nitrogen-donor ligand such as ammine, ethylenediamine (en), pyridine (py), 1,10-phenanthroline (phen), 2,2-bipyridine (bipy) or 1,4,8,11-tetra-azacyclotetradecane (cyclam), 2,3,7,8,12,13,17,18-octaethylporphyrin (oep) or a combination of these.
  • en ethylenediamine
  • pyridine py
  • 1,10-phenanthroline phen
  • the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of formula IV wherein Y IV is a nitrogen-donor ligand selected from the group en, py, phen, bipy, cyclam and oep. Derivations of these ligands can be prepared by a skilled addressee and which will fall within the scope of the inventions.
  • metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium or osmium of general formula
  • Y V is a combination of donor ligands such as are described hereinabove, for example ammine, dmso, oxalate, bipy, acac and MeCN.
  • Complexes of formula V are present in for example
  • the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of formula [Os(ox)(bipy) 2 ]; and further a pharmaceutical composition containing an optionally hydrated complex of formula [Ru(acac) 2 (MeCN) 2 ] + .
  • the complexes of the present invention may be included as an active component in a pharmaceutical composition containing an optionally hydrated complex of any of formulae I-V, in admixture with a pharmaceutically acceptable carrier or diluent.
  • Said pharmaceutical composition may be formulated according to well known principles, and may be in the form of a solution or suspension for parenteral administration in single or repeat doses or be in capsule, tablet, dragee, or other solid composition or as a solution or suspension for oral administration, or formulated into pessaries or suppositories, or sustained release forms of any of the above.
  • the solution or suspension may be administered by a single or repeat bolus injection or continuous infusion, or any other desired schedule.
  • Suitable diluents, carriers, excipients and other components are known.
  • Said pharmaceutical composition may contain dosages determined in accordance with conventional pharmacological methods, suitable to provide active complexes in the dosage range in humans of 1 mg to 10 g per day. Actual required dosage is largely dependent on where in the body there is the excess concentration of NO and for how long overproduction continues or attenuation of NO levels, where NO is implicated in disease, is required.
  • Example Compound Literature Reference for Preparation 1 K[Ru(Hedta)Cl]2H 2 O AA Diamantis & JV Dubrawski, Inorg.Chem., (1981), 20, 1142-50 2 [Ru(H 2 edta)(acac)] AA Diamantis & JV Dubrawski, Inorg.Chem., (1983), 22, 1934-36 3 K[Ru(hedtra)Cl]H 2 O HC Bajaj & R van Eldik, Inorg.Chem.(1982), 28, 198O-3 4 K[Ru(dipic) 2 ]H 2 O NH Williams & JK Yandell, Aust.J.Chem.(1983), 36(12), 23
  • K[S 2 P(OC 2 H 4 OC 2 H 4 OMe) 2 ] 3 was made by standard method and crystallised from methanol in 76% yield.
  • each compound (1 ⁇ 10 4 moles) was dissolved in double-distilled deionized and deoxygenated water.
  • the resulting solution was placed in a three-necked pear-shaped flask and stirred by a magnetic stirrer at constant speed of 1000 rpm, at a constant temperature in the range 20° C.-24° C.
  • a manometer was attached to the flask, and purified, dried nitric oxide gas (known volume in the range 3-5 cm 3 ) was introduced via a septum, using a gas syringe, at atmospheric pressure into the headspace above the reaction solution. The pressure within the flask was recorded periodically over a period of one hour.
  • murine (RAW264) macrophage cell lines which can be induced to produce nitric oxide, were seeded, 10 6 cells/well, onto 24 well culture plates of 2 ml volume per well, in Eagles modified minimal essential medium (MEM) plus 10% foetal bovine serum without phenol red.
  • MEM Eagles modified minimal essential medium
  • the cells were activated to produce nitric oxide, with 10 ⁇ g/ml lipopolysaccharide and 100 units/ml interferon ⁇ for 18 hours. Concurrently, test compounds made up in MEM were added at non-cytotoxic concentrations.
  • Nitric oxide was determined by measurement of nitrate and nitrite in the cell supernatant. These anions are the stable end-products of reactions of NO in solution. Such reactions may or may not be catalysed in biological systems. The sum of nitrite and nitrate concentrations gives the total NO production. Nitrite was determined using the Griess reaction in which nitrite reacts with 1% sulphanilamide in 5% H 3 PO 4 /0.1% naphthylethylenediamine dihydrochloride to form a chromophore absorbing at 540 nm.
  • Nitrate was determined by reducing nitrate to nitrite with a bacterial nitrate reductase from Pseudomonas oleovorans and then measuring nitrite with the Griess reaction. In the absence of test compounds nitrite concentration plus nitrate concentration is equal to total nitric oxide production. The effect of test compounds on available nitric oxide (measured as nitrite+nitrate) was detemined. The reduction in available nitric oxide compared with the control level may be taken as an indication of the degree of binding of NO by the test compounds.
  • rat tail artery segments of rat tail artery (0.8-1.5 cm) were dissected free from normotensive adult Wistar rats.
  • the arteries were internally perfused with Krebs solution (mM: NaCl 118, KCl 4.7, NaHCO 3 25, NaH 2 PO 4 1.15, CaCl 2 2.5, MgCl 2 1.1, glucose 5.6 and gassed with 95% O 2 /5% CO 2 to maintain a pH of 7.4) in a constant flow perfusion apparatus.
  • a differential pressure transducer located upstream of the vessel detected changes in back pressure.
  • the rat tail artery preparation was pre-contracted with 6.5 ⁇ M phenylephrine to give a physiologically normal pressure of 100-120 mm Hg.
  • the pre-contracted vessels were then perfused with the test compound.
  • the arteries were perfused with Krebs solution between applications of test compound to wash out the test compound.
  • vasoconstriction is a direct result of the removal of endogenous nitric oxide (edrf) from the endothelial cells of the rat tail artery.
  • edrf endogenous nitric oxide
  • test compound resulted in a dose-dependent vasoconstriction at 10 ⁇ M and 100 ⁇ M. This effect was reversible by washout with Krebs solution.
  • test compound resulted in a dose-dependent vasoconstriction at 10 ⁇ M and 100 ⁇ M. This effect was reversible by washout with Krebs solution.
  • test compound resulted in a dose-dependent vasoconstriction at 10 ⁇ M and 100 ⁇ M. This effect was reversible by washout with Krebs solution.
  • test compound resulted in a dose-dependent vasoconstriction at 10 ⁇ M and 100 ⁇ M. This effect was reversible by washout with Krebs solution.

Abstract

New pharmaceutical compositions and pharmaceutical compositions comprising metal complexes have activity against diseases caused by or related to overproduction or localized high concentration of nitric oxide in the body.

Description

  • This invention relates to new pharmaceutical compositions and to pharmaceutical compositions having activity against diseases caused by or related to overproduction or localised high concentration of nitric oxide in the body. [0001]
  • Nitric oxide (NO) plays a varied and vital role in the human body. For example, NO plays a vital role in the control of blood pressure; it acts as a neurotransmitter; it plays a role in inhibition of platelet aggregation (important in thrombosis or blockages of the blood vessels), and in cytostasis (important in fighting of tumours). Overproduction of NO however, has been implicated in a number of disease states, including vascular/pressor diseases such as septic shock, post-ischaemic cerebral damage, migraine, and dialysis induced renal hypotension; immunopathologic diseases such as hepatic damage in inflammation and sepsis, allograft rejection, graft versus host diseases, diabetes and wound healing; neurodegenerative diseases such as cerebral ischaemia, trauma, chronic epilepsy, Alzheimer's disease, Huntington's disease, and AIDS dementia complex; and side effects of treatment such as restenosis following angioplastic treatment and secondary hypotension following cytokine therapy. [0002]
  • Pharmacological modulation of nitric oxide in any of these disease states should prove extremely beneficial. [0003]
  • One above-mentioned disease relating to overproduction of NO, is septic shock. This is precipitated by local septicaemia or endotoxaemia, (high local levels of bacterial endotoxins). The result is activation of macrophages, lymphocytes, endothelial cells and other cell types capable of producing NO, further mediated by cytokine production by these cells. The activated macrophages produce excess NO which causes vasodilation of the blood vessels, and results in local vascular damage and vascular collapse. This destruction of vascular integrity may be so great that it leads to the collapse of haemodynamic homeostasis, the end result being death. [0004]
  • Current ideas for pharmacological modulation of nitric oxide in such diseases are based on dealing with the mediators of septic shock, such as cytokines, endotoxins, and platelet activating factor (PAF). The approaches include use of antibodies to cytokines such as tumour necrosis factor (TNF), receptor antagonists such as [0005] interleukin 1, (IL-1), antibodies to lipopolysaccharide (the endotoxin produced by gram negative bacteria, and PAF antagonists. All such approaches while challenging a factor mediating septic shock, do not attempt to deal with the aetiology, or cause, of the disease. Recent advances in understanding of NO have lead to the proposal that inhibitors of the NO synthase enzyme, such as NG-monomethy-L-arginine (L-NMMA), may be useful in the treatment of septic shock and other NO overproduction related to diseases since they inhibit NO production. While these inhibitors have shown some utility in animal models and preliminary clinical studies, they have the disadvantage of undesirably inhibiting total NO synthesis in the body.
  • An aim of the present invention is to provide new and previously indicated pharmaceutical compositions which are able to modulate NO levels in the body by scavenging, or removing, NO in situ so that necessary NO synthesis continues while dangerous excesses are removed. We have found that certain metal complexes have the ability to carry out this important role. [0006]
  • Some metal complexes are known in pharmaceutical compositions for the treatment of diseases of the human body. For example, certain complexes of platinum and ruthenium have been used or indicated in the treatment of cancer. Metal complexes have not however been previously indicated in the treatment of NO overproduction related diseases. [0007]
  • This invention provides for the use of a neutral, anionic or cationic metal complex having at least one site for coordination with NO, of formula[0008]
  • [Ma(XbL)cYdZe]a±  formula I,
  • in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, [0009]
  • where: [0010]
  • M is a metal ion or a mixture of metal ions; [0011]
  • X is a cation or a mixture of cations; [0012]
  • L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic Table; [0013]
  • Y is a ligand, or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom, which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table; [0014]
  • and [0015]
  • Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions; [0016]
  • a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10; [0017]
  • provided that at least one of c, d and e is 1 or more; [0018]
  • and where c is 0; b is also 0; [0019]
  • and where a is 1; c, d and e are not greater than 9; [0020]
  • and where a is 2; c, d and e are not greater than 12. [0021]
  • By “complex” in this specification is meant a neutral complex or anionic or cationic species. [0022]
  • The term “Group” which is used herein is to be understood as a vertical column of the periodic table in which elements of each Group have similar physical and chemical properties. The definition of the Periodic Table is that credited to Mendeleev; Chambers Dictionary of Science and Technology, 1974. Published by W & R Chambers Ltd. [0023]
  • This invention may also be stated as providing a method of attenuation of NO levels where NO is implicated in diseases of the human body, comprising administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of formula I. [0024]
  • This invention may also provide for the use of a neutral, anionic or cationic metal complex of formula I in the manufacture of a medicament for the treatment of NO overproduction related disease. [0025]
  • This invention may also be stated as providing a method of treatment of diseases of the human body resultant of overproduction of NO in the human body, comprising administering a pharmaceutical composition containing a neutral, anionic or cationic metal complex of formula I. [0026]
  • Where the formula I represents an anionic species, a cation will also be present. Where formula I represents a cationic species, an anion will also be present. The metal complexes may be hydrated. [0027]
  • Preferably, M is a first, second or third row transition metal ion. For example, M may be an Rh, Ru, Os, Mn, Co, Cr or Re ion, and is preferably an Rh, Ru or Os ion. [0028]
  • Suitably M is in an oxidation state III. We have found surprisingly that when the metal ion for example ruthenium is in oxidation state III, the rate at which it binds with NO is significantly faster than when it is in oxidation state II. [0029]
  • X may be any cation, such as a mono-, di- or tri-valent cation. Suitable cations may be H[0030] +, K+, Na+, NH4 + or Ca2+. Conveniently X may be H+, K+ or Na+.
  • Preferably, L is a ligand containing both nitrogen and oxygen donor atoms. Examples of suitable such ligands include ethylenediamine -N,N′-diacetic acid (edda), ethylenediaminetetraacetic acid (edta), nitrilotriacetic acid (nta), dipicolinic acid (dipic), picolinic acid (pic), diethylenetriaminepentaacetic acid (dtpa), thiobis(ethylenenitrilo)tetraacetic acid (tedta), dithioethanebis(ethylenenitrilo) tetraacetic acid (dtedta) anid N-(2-hydroxyethyl)ethylenediamine-triacetic acid (hedtra). [0031]
  • Preferably, Y is a ligand containing nitrogen, oxygen, sulphur, carbon, or phosphorus donor groups. Suitable nitrogen donor groups may be for example ammine, amine, nitrile and nitride or derivations thereof. Suitable oxygen donor groups may be for example carboxylic acid, ester or derivations thereof, water, oxide, sulphoxide, hydroxide, acetate, lactate, propionate, oxalate and maltolate. Suitable sulphur donor groups may be for example sulphoxide, dialkylsulphide, dithiocarbarnate or dithiophosphate. Suitable carbon donor groups may be for example carbon monoxide or isocyanide. Suitable phosphorus donor groups may be for example triallylphosphine. [0032]
  • Z may be any halide and is preferably chloride, bromide or iodide. Most conveniently, Z is chloride. [0033]
  • Examples of metal complexes for use according to the present invention include optionally hydrated ruthenium complexes of formula[0034]
  • [Ru(H0-6L″)1-3Y0-2Cl0-4](0-4)±  formula II,
  • where L″ is an amide or ester or derivative thereof, or a polydentate aminocarboxylate ligand, for example edta, nta, dipic, pic, edda, tropolone, dtpa, hedtra, tedta or dtedta or diamide of edta or dtpa or a mixture of any of these, and Y is as defined above and may for example be selected from acetylacetone (acac), a β-diketonate, water, dimethylsulphoxide (dmso), carboxylate, bidentate carboxylate, catechol, kojic acid, maltol, hydroxide, tropolone, malonic acid, oxalic acid, 2,3-dihydroxynaphthalene, squaric acid, acetate, a sulphate and a glycolate. The skilled addressee will be able to substitute other known ligands at Y and which will fall within the scope of the inventions. Preparative methods of tedta, dtedta and diamide of edta and dtpa are described in the following references respectively: [0035]
  • P Tse & J E Powell, Inorg Chem, (1985), 24, 2727 [0036]
  • G Schwartzenbach, H Senner, G Anderegg, [0037] Helv Chim Acta 1957, 40, 1886
  • M S Konings, W C Dow, D B Love, K N Raymond, S C Quay and S M Rocklage, Inorg Chem (1990), 29, 1488-1491 [0038]
  • P N Turowski, S J Rodgers, R C Scarrow and K N Raymond, Inorg Chem (1988), 27, 474-481. [0039]
  • Where the complex of formula II is an anion, a cation will be required. For example the complexes of formula II are present in [0040]
  • K[Ru(Hedta)Cl]2H[0041] 2O
  • [Ru(H[0042] 2edta)(acac)]
  • K[Ru(hedtra)Cl]H[0043] 2O
  • K[Ru(dipic)[0044] 2]H2O
  • (H[0045] 2pic)[RuCl2(pic)2](Hpic)H2O
  • K[Ru(H[0046] 2edta)Cl2]H2O
  • K[Ru(Hnta)[0047] 2]½H2O
  • K[Ru(H[0048] 2dtpa)Cl]H2O
  • [Ru(Hhedtra)acac]H[0049] 2O
  • [Ru(Hhedtra)trop][0050]
  • [Ru(H[0051] 3dtpa)Cl]
  • Complexes of formula II have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated ruthenium complex of formula II. [0052]
  • Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of formula III[0053]
  • [M1-3Y1-18Cl0-18](0-6)±  formula III
  • Where Y is a sulphur donor ligand. For example, such complex is present in [0054]
  • [Ru(mtc)[0055] 3] (mtc=4-morpholinecarbodithoic acid)
  • Ru(S[0056] 2CNCH2CH2NMeCH2CH2)3½H2O
  • Complexes of formula III in which Y is a sulphur donor ligand have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore, the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of formula III wherein Y is a sulphur donor ligand. [0057]
  • Yet further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of formula[0058]
  • [M′″1-3Y′″1-18Cl0-18](0-6)±  formula III
  • where M′″ is ruthenium and Y′″ is an oxygen-donor ligand such as acetate, lactate, water, oxide, propionate (COEt), oxalate (ox), or maltolate (maltol) or a combination of these. For example complexes of formula III are present in [0059]
  • [RU[0060] 3O(OAC)6](OAc)
  • [RU[0061] 3O(lac)6](lac)
  • [Ru[0062] 2(OAc)4]NO3
  • [Ru[0063] 2(OCOEt)4]NO3
  • K[0064] 3[Ru(ox)3]
  • [RU[0065] 2(OAc)4]Cl
  • [Ru(maltol)[0066] 3]
  • Some complexes of formula III have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of formula III wherein M′″ is ruthenium and Y′″ is an oxygen-donor ligand selected from the group acetate, lactate, oxide, propionate and maltolate. [0067]
  • Further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium of formula[0068]
  • [RuYIV 1-9Cl1-9](0-4)±  formula IV
  • where Y[0069] IV is a nitrogen-donor ligand such as ammine, ethylenediamine (en), pyridine (py), 1,10-phenanthroline (phen), 2,2-bipyridine (bipy) or 1,4,8,11-tetra-azacyclotetradecane (cyclam), 2,3,7,8,12,13,17,18-octaethylporphyrin (oep) or a combination of these. For example complexes of formula IV are present in
  • [RU(NH[0070] 3)5Cl]Cl2
  • [Ru(en)[0071] 3]I3
  • trans-[RuCl[0072] 2(py)4]
  • K[Ru(phen)Cl[0073] 4]
  • [Ru(cyclam)Cl[0074] 2]Cl
  • K[Ru(bipy)Cl[0075] 4]
  • [Ru(NH[0076] 3)6]Cl3
  • [Ru(NH[0077] 3)4Cl2]Cl
  • Ru(oep)Ph [0078]
  • Some complexes of formula IV have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of ruthenium of formula IV wherein Y[0079] IV is a nitrogen-donor ligand selected from the group en, py, phen, bipy, cyclam and oep. Derivations of these ligands can be prepared by a skilled addressee and which will fall within the scope of the inventions.
  • Still further examples of metal complexes for use according to the present invention include optionally hydrated complexes of ruthenium or osmium of general formula[0080]
  • [M1-3YV 1-18Cl0-18](0-6)±  formula V
  • where Y[0081] V is a combination of donor ligands such as are described hereinabove, for example ammine, dmso, oxalate, bipy, acac and MeCN. Complexes of formula V are present in for example
  • [Ru(NH[0082] 3)(dmso)2Cl3]
  • cis-[Ru(dmso)[0083] 4Cl2]
  • cis-[Ru(NH[0084] 3)(dmso)3Cl2]
  • [Ru(dmso)[0085] 3Cl3]
  • [Os(ox)(bipy)[0086] 2]H2O
  • [Ru(acac)[0087] 2(MeCN)2]CF3SO3
  • The complex ions of the latter two compounds above have not to the best of our knowledge been previously indicated in any pharmaceutical composition. Therefore the present invention also provides a pharmaceutical composition containing an optionally hydrated complex of formula [Os(ox)(bipy)[0088] 2]; and further a pharmaceutical composition containing an optionally hydrated complex of formula [Ru(acac)2(MeCN)2]+.
  • In use the complexes of the present invention may be included as an active component in a pharmaceutical composition containing an optionally hydrated complex of any of formulae I-V, in admixture with a pharmaceutically acceptable carrier or diluent. Said pharmaceutical composition may be formulated according to well known principles, and may be in the form of a solution or suspension for parenteral administration in single or repeat doses or be in capsule, tablet, dragee, or other solid composition or as a solution or suspension for oral administration, or formulated into pessaries or suppositories, or sustained release forms of any of the above. The solution or suspension may be administered by a single or repeat bolus injection or continuous infusion, or any other desired schedule. Suitable diluents, carriers, excipients and other components are known. Said pharmaceutical composition may contain dosages determined in accordance with conventional pharmacological methods, suitable to provide active complexes in the dosage range in humans of 1 mg to 10 g per day. Actual required dosage is largely dependent on where in the body there is the excess concentration of NO and for how long overproduction continues or attenuation of NO levels, where NO is implicated in disease, is required. [0089]
  • This invention will now be illustrated by Example. [0090]
  • A number of commercially available compounds, and compounds prepared by routes known in the literature, containing the complexes of the present invention were tested in vitro, in vitro cell culture, and ex-vivo in order to determine ability to coordinate with NO. The complexes tested were as follows: [0091]
    Example Compound Literature Reference for Preparation
    1 K[Ru(Hedta)Cl]2H2O AA Diamantis & JV Dubrawski,
    Inorg.Chem., (1981), 20, 1142-50
    2 [Ru(H2edta)(acac)] AA Diamantis & JV Dubrawski,
    Inorg.Chem., (1983), 22, 1934-36
    3 K[Ru(hedtra)Cl]H2O HC Bajaj & R van Eldik,
    Inorg.Chem.(1982), 28, 198O-3
    4 K[Ru(dipic)2]H2O NH Williams & JK Yandell,
    Aust.J.Chem.(1983), 36(12), 2377-2386
    5 (H2pic)[RuCl2(pic)2](Hpic)H2O JD Gilbert, D Rose & G Wilkinson,
    J.Chem.Soc.(A), (1970), 2765-9
    6 K[Ru(H2edta)Cl2]H2O AA Diamantis & JV Dubrawski,
    Inorg.Chem.(1981), 20, 1142-50
    7 K[Ru(Hnta)2]1/2H2O MM Taqui Khan, A Kumar &
    Z Shirin,
    J. Chem. Research (M), (1986), 1001-
    1009
    8 K[Ru(H2dtpa)Cl]H2O MM Taqui Khan, A Kumar &
    Z Shirin,
    J. Chem. Research (M). (1986); 1001-
    1009
    9 [Ru3O(lac)6](lac) A Spencer & G Wilkinson,
    J. Chem. Soc. Dalton Trans. (1972),
    1570-77
    10 [Ru3O(OAc)6](OAc) A Spencer & G Wilkinson,
    J.Chem. Soc. Dalton Trans. (1972),
    1570-77
    11 [Ru2(OAc)4]NO3 M Mukaida, T Nomura & T Ishimori,
    Bull. Chem. Soc. Japan, (1972), 45,
    2143-7
    12 [Ru2(OCOEt)4]NO3 A Bino, FA Cotton & TR Felthouse,
    Inorg. Chem. (1979), 18, 2599-2604
    13 K3[Ru(ox)3] CM Che, SS Kwong, CK Poon,
    TF Lai & TCW Mak
    Inorg. Chem. (1985), 24, 1359-63
    14 [Ru2(OAc)4Cl RW Mitchell, A Spencer &
    G Wilkinson
    J. Chem. Soc. Dalton Trans., (1973),
    846-54
    15 [Ru(NH3)5Cl]Cl2 AD Allen, F Bottomley, RO Harris,
    VP Reinsahu & CV Senoff
    J. Amer. Chem. Soc. (1967), 89,
    5595-5599
    16 [Ru(en)3]I3 TJ Meyer & H Taube
    Inorg. Chem. (1968), 7, 2369-2379
    17 K[RuCL4(phen)]H2O BR James & RS McMillan
    Inorg. Nucl. Chem. Lett. (1975),
    11(12) 837-9
    18 [Ru(cyclam)Cl2]Cl PK Chan, DA Isabirye & CK Poon
    Inorg. Chem. (1975), 14, 2579-80
    19 K[RuCl4(bipy)] BR James & RS McMillan
    Inorg. Nucl. Chem. Lett. (1975),
    11(12), 837-9
    20 [RuCl3(dmso)2(NH3)] Patent: International Publication No
    WO 91/13553
    21 [Ru(NH3)6]Cl3 Matthey Catalogue Sales: Cat No
    [190245]
    22 cis-[RuCl2(dmso)4] EA Alessio, G Mestroni, G Nardin,
    WM Attia, M Calligaris, G Sava &
    S Zorget
    Inorg. Chem. (1988), 27, 4099-4106
    23 cis-[RuCl2(dmso)3(NH3)] M Henn, E Alessio, G Mestroni,
    M Calligaris & WM Attia
    lnorg. Chim. Acta, (1991), 187, 39-50
    24 [RuCl3(dmso)3] E Alessia, G Balducci, M Calligalis,
    G Costa, WM Attia & G Mestroni
    Inorg. Chem. (1991), 30, 609-618
    25 [Ru(mtc)3] AR Hendrickson, JM Hope &
    RL Martin
    J. Chem. Soc. Dalton Trans. (1976),
    20, 2032-9
    26 [Ru(maltol)3] WP Griffith & SJ Greaves
    Polyhedron, (1988), 7(19) 1973-9
    27 [Ru(acac)2(MeCN)2]CF3SO3 Y Kasahara, T Hoshino, K Shimizu &
    GP Sato
    Chem. Lett. (1990), 3, 381-4
    28 K2[RuCl5(H2O)] Matthey Catalogue Sales: Cat No
    [190094]
    29 [Os(ox)(bipy)J].H2O DA Buckingharn, FP Dwyer,
    HA Goodwin & AM Sargeson
    Aust.J.Chem.(1964), 325-336
    GM Bryant, JE Fergusson &
    HKJ Powell
    Aust.J.Chem.(1971), 24(2), 257-73
    30 [Ru(NH3)4Cl2]Cl SD Pell, MM Sherban, V Tramintano
    & MJ Clarke
    Inorg Synth, (1989), 26, 65.
    31 [Ru(Hedtra)(dppm)] MM Taqui Khan,
    K Venkatasubramanian, Z Shirin,
    MM Bhadbhade
    J Chem Soc Dalt Trans (1992), 885-890
    32 Ru(oep)Ph M Ke, SJ Rettig, BR James and
    D Dolphin
    J Chem Soc Chem Commun (1987),
    1110
  • A number of new compounds were prepared according to the following protocols. The first four compounds are examples of ruthenium complexes of formula [Ru(H[0092] 0-6L″)1-3 Y0-2Cl0-4](0-4)± formula II), the subsequent two are examples of [M1-3Y1-8Cl0-18](0-6)± (formula III).
  • Preparation of [Ru(Hhedtra)acac].H[0093] 2O
  • Excess acetylacetone (1 cm[0094] 3) was added to an aqueous solution (5 cm3) of K[Ru(hedtra)Cl] (0.5 g). The solution colour changed to violet. The mixture was warmed for 20 minutes then left to stand at room temperature for 20 minutes. The violet solution was extracted with chloroform (20 cm3). The extraction was repeated twice more. A violet product precipitated from the aqueous fraction. The product was filtered, washed in acetone and dried in vacuo, yield 0.1 g (18%).
  • Anal. Calc. for C[0095] 15H25O10N2Ru: C, 36.43; H, 5.11; N, 5.70. Found: C, 36.16; H 5.42; N, 5.61%.
  • Preparation of [Ru(Hhedtra)trop]2H[0096] 2O
  • A three-fold excess of tropolone (0.78 g) dissolved in 50:50 water/absolute ethanol (5 cm[0097] 3) was added to a warm aqueous solution of K[Ru(hedtra)Cl] (10 cm3). The mixture was heated for 1 hour. On cooling, the dark green mixture was extracted with 3×20 cm3 portions of dichloromethane. On standing, a dark green product precipitated from the aqueous fraction. The product was filtered, washed with water (1 cm3), ether and dried in vacuo, yield 0.4 g (36%).
  • Anal. Calc. for C[0098] 17H22N2O9Ru0.2H2O: C, 38.13; H, 4.86; N, 5.23. Found: C, 38.55; H, 4.67; N, 5.28%.
  • Preparation of [Ru(H[0099] 3dtpa)Cl]
  • K[0100] 2[RuCl5H2O].xH2O (1 g) was suspended in HClO4 (15 cm3, 1 mM) and diethylenetriaminepentaacetic acid (1.05 g) added. The reaction mixture was heated under reflux for 1.5 hours forming a yellow/brown solution. On cooling a yellow product crystallised which was collected by filtration, washed with 90% absolute ethanol/water, diethyl ether and dried in vacuo, yield 0.75 g, 53%.
  • Anal. calcd. for C[0101] 14H21N3O10ClRu: C, 31.85; H, 3.98; N, 7.96; Cl, 6.73. Found: C, 29.77; H, 3.81; N, 7.36; Cl, 6.64.
  • Preparation of K[RuHHBEDCl]3H[0102] 2O
  • 0.41 g of K[0103] 2[RuCl5]xH2O was dissolved in water (20 ml). To this solution was added 1 equivalent (0.39 g) of N,N′di(2-hydroxy-benzyl)ethylene-diamine N,N-dacetic acid (hbed) dissolved in water (50 ml) with KOH (0.12 g) and MeOH (1 ml). This miixture was heated at reflux for 90 minutes. Upon cooling a dark, insoluble precipitate formed. This material was removed by filtration and the resulting red-violet solution was taken to dryness by rotary evaporation. Trituration with water and washing with acetone yielded 90 mg of a dark solid.
  • Anal. calcd. for C[0104] 18H22N2O9RuClK: C, 36.89; H, 3.96; N, 4.78; Cl, 6.04. Found: C, 37.09; H, 4.23; N, 4.92; Cl, 6.28.
  • Preparation of Ru(S[0105] 2CNCH2CH2NMeCH2CH2)3½H2O
  • Me[0106] 4N[S2CNCH2CH2NMeCH2CH2] was made by the standard method and crystallised from methanol-ether in 71% yield.
  • RuCl[0107] 3xH2O, 0.50 g, 2.15 mmol was refluxed in 30 ml of methanol for 10 minutes and cooled. 1.87 g, 7.50 mmol of Me4N[S2CNCH2CH2NMeCH2CH2] was added and the mixture refluxed for 16 hours. After cooling 0.72 g of crude product was filtered off, dissolved in dichloromethane and filtered. The filtrate was loaded into 15 cc of basic alumina and eluted with dichloromethane. Removal of solvent and crystallisation from dichloromethane with ether by vapour-phase diffusion gave 0.51 g, 0.80 mmol, 37% of brown-black crystals, Ru(S2CNCH2CH2NMeCH2CH2)3 {fraction (1/2)}H 2O.
  • Analysis for C[0108] 18H34N6O5RuS6: Calc: C, 34.00; H, 5.39; N, 13.22; S, 30.25. Found: C, 34.21; H, 5.47; N, 13.12; S, 30.36.
  • Preparation of Ru[S[0109] 2P(OC2H2OC2H4OMe)2]3
  • K[S[0110] 2P(OC2H4OC2H4OMe)2]3was made by standard method and crystallised from methanol in 76% yield.
  • RuCl[0111] 3xH2O, 1.00 g, 4.30 mmol was refluxed in 50 ml of 0.1 N HCl with 1 ml of ethanol for 20 minutes and cooled. To this solution was added 5.28 g (excess) K[S2P(OC2H4OC2H4OMe)2] and the mixture stirred at 30° C. for 1 hour. the reaction mixture was extracted with dichloromethane and the solvent removed. The residue was extracted with ether-hexane and solvents removed. This residue was crystallised from 25 ml of hot ether by cooling to −20° C. giving 2.98 of red crystals. 2.41 g of the crude product was purified by chromatography on 60 cc of silica gel with 5% ethanol in ether. The first band was collected, reduced to dryness and crystallised from ether by cooling to −20° C. The yield of red crystals, Ru(S2P{OC2H4OC2H4OMe}2)3, was 2.16 g, 56%.
  • Analysis for C[0112] 30H60O18P3RuS6: Calc: C, 32.72; H, 6.04; S, 17.47. Found: C, 32.68; H, 6.08; S, 17.16.
  • In the in vitro tests, which were carried out in an atmosphere of argon, each compound (1×10[0113] 4 moles) was dissolved in double-distilled deionized and deoxygenated water. The resulting solution was placed in a three-necked pear-shaped flask and stirred by a magnetic stirrer at constant speed of 1000 rpm, at a constant temperature in the range 20° C.-24° C. A manometer was attached to the flask, and purified, dried nitric oxide gas (known volume in the range 3-5 cm3) was introduced via a septum, using a gas syringe, at atmospheric pressure into the headspace above the reaction solution. The pressure within the flask was recorded periodically over a period of one hour.
  • A control experiment was carried out according to the above but without any complex present. [0114]
  • The recorded pressures in association with the results of the control experiment were analysed in order to determine the rate of NO uptake as a function of time for each compound tested. [0115]
  • On completion of each in vitro test, the reaction solution was freeze-dried. An infrared spectrum of the freeze-dried product provided information on metal-NO bond formation. [0116]
  • In the in vitro cell culture tests, murine (RAW264) macrophage cell lines, which can be induced to produce nitric oxide, were seeded, 10[0117] 6cells/well, onto 24 well culture plates of 2 ml volume per well, in Eagles modified minimal essential medium (MEM) plus 10% foetal bovine serum without phenol red.
  • The cells were activated to produce nitric oxide, with 10 μg/ml lipopolysaccharide and 100 units/ml interferon γ for 18 hours. Concurrently, test compounds made up in MEM were added at non-cytotoxic concentrations. [0118]
  • Control cells as above, which were activated to produce nitric oxide as above, but to which no test compound was added, were used as a measure of the amount of nitric oxide produced by the cells during the tests. [0119]
  • Background nitric oxide was assessed by measurement of nitrate and nitrite in cells which were not activated. [0120]
  • Cell viability was confirmed by Trypan blue dye exclusion at the end of the incubation period. [0121]
  • Nitric oxide was determined by measurement of nitrate and nitrite in the cell supernatant. These anions are the stable end-products of reactions of NO in solution. Such reactions may or may not be catalysed in biological systems. The sum of nitrite and nitrate concentrations gives the total NO production. Nitrite was determined using the Griess reaction in which nitrite reacts with 1% sulphanilamide in 5% H[0122] 3PO4/0.1% naphthylethylenediamine dihydrochloride to form a chromophore absorbing at 540 nm. Nitrate was determined by reducing nitrate to nitrite with a bacterial nitrate reductase from Pseudomonas oleovorans and then measuring nitrite with the Griess reaction. In the absence of test compounds nitrite concentration plus nitrate concentration is equal to total nitric oxide production. The effect of test compounds on available nitric oxide (measured as nitrite+nitrate) was detemined. The reduction in available nitric oxide compared with the control level may be taken as an indication of the degree of binding of NO by the test compounds.
  • In the ex vivo tests, segments of rat tail artery (0.8-1.5 cm) were dissected free from normotensive adult Wistar rats. The arteries were internally perfused with Krebs solution (mM: NaCl 118, KCl 4.7, NaHCO[0123] 3 25, NaH2PO4 1.15, CaCl2 2.5, MgCl2 1.1, glucose 5.6 and gassed with 95% O2/5% CO2 to maintain a pH of 7.4) in a constant flow perfusion apparatus. A differential pressure transducer located upstream of the vessel detected changes in back pressure. The rat tail artery preparation was pre-contracted with 6.5 μM phenylephrine to give a physiologically normal pressure of 100-120 mm Hg. The pre-contracted vessels were then perfused with the test compound. The arteries were perfused with Krebs solution between applications of test compound to wash out the test compound.
  • Pressure changes in the system served to indicate artery vasoconstriction. The vasoconstriction is a direct result of the removal of endogenous nitric oxide (edrf) from the endothelial cells of the rat tail artery. [0124]
    • RESULTS
  • The results of the in vitro, in vitro cell culture and ex-vivo tests were as follows: [0125]
  • In Vitro Tests[0126]
    • EXAMPLE 1 K[Ru(Hedta)Cl]2H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0127]
  • The IR spectrum showed a peak at 1897 cm[0128] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 2 [Ru(H2edta)(acac)]
  • The IR spectrum showed a peak at 1896 cm[0129] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 3 K[Ru(hedtra)Cl]H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0130]
  • The IR spectrum showed a peak at 1889 cm[0131] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 4 K[Ru(dipic)2]H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0132]
  • The IR spectrum showed a peak at 1915 cm[0133] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 5 (H2pic)[RuCl2(pic)2](Hpic)H2O
  • The IR spectrum showed a peak at 1888 cm[0134] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 6 K[Ru(H2edta)Cl2]H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0135]
  • The IR spectrum showed a peak at 1896 cm[0136] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 7 K[Ru(Hnta)2]½H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0137]
  • The IR spectrum showed a peak at 1889 cm[0138] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 8 K[Ru(H2dtpa)Cl]H2O
  • A pressure decrease indicated binding of NO to the metal compound. This is illustrated in FIG. 1. [0139]
  • The IR spectrum showed a peak at 1905 cm[0140] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 9 [Ru3O(lac)6](lac)
  • The IR spectrum showed a peak at 1884 cm[0141] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 10 [Ru3(OAc)6](OAc)
  • The IR spectrum showed a peak at 1877 cm[0142] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 11 [RU2(OAc)4]NO3
  • The IR spectrum showed a peak at 1891 cm[0143] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 12 [Ru(OCOEt)4]NO3
  • The IR spectrum showed a peak at 1891 cm[0144] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 13 K3[Ru(ox)3]
  • The IR spectrum showed a peak at 1889 cm[0145] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 14 [Ru2(OAc)4]Cl
  • The IR spectrum showed a peak at 1895 cm[0146] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 15 [Ru(NH3)5Cl]Cl2
  • The IR spectrum showed two peaks at 1909 cm[0147] −1 and 1928 cm−1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 16 [Ru(en)3]I3
  • The IR spectrum showed a peak at 1906 cm[0148] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 17 K[RuCl4(phen)]H2O
  • The IR spectrum showed a peak at 1904 cm[0149] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 18 [Ru(cyclam)Cl2]Cl
  • The IR spectrum showed a peak at 1895 cm[0150] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 19 K[RuCl4(bipy)]
  • The IR spectrum showed a peak at 1885 cm[0151] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 20 [RuCl3(dmso)2(NH3)]
  • The IR spectrum showed a peak at 1889 cm[0152] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 21 [Ru(NH3)6]Cl3
  • The IR spectrum showed a peak at 1918 cm[0153] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 22 cis-[RuCl2(dmso)4]
  • The IR spectrum showed a peak at 1881 cm[0154] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 23 cis-[RuCl2(dmso)3(NH3)]
  • The IR spectrum showed a peak at 1893 cm[0155] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 24 [RuCl3(dmso)3]
  • The IR spectrum showed a peak at 1880 cm[0156] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 25 [Ru(mtc)3]
  • The IR spectrum showed a peak at 1862 cm[0157] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 26 [Ru(maltol)3]
  • The IR spectrum showed a peak at 1866 cm[0158] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 27 [Ru(acac)2(MeCN)2]CF3SO3
  • The IR spectrum showed a peak at 1899 cm[0159] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 28 K2[RuCl5(H2O)]
  • The IR spectrum showed a peak at 1903 cm[0160] −1, indicating the presence of a Ru—NO bond.
    • EXAMPLE 29 [Os(ox)(bipy)2]H2O
  • The IR spectrum showed a peak at 1894 cm[0161] −1, indicating the presence of a Os—NO bond.
  • In Vitro Cell Culture Tests [0162]
  • Results are shown in Table 1 and FIG. 2. [0163]
    • EXAMPLE 1 K[Ru(Hedta)Cl]2H2O
  • Available nitric oxide was reduced in a dose-dependent fashion with a maximum reduction of 75% at a concentration of 100 μM. [0164]
    • EXAMPLE 2 [Ru(H2edta)(acac)]
  • Available nitric oxide was reduced by 82% at 100 μM test compound. [0165]
    • EXAMPLE 3 K[Ru(Hedtra)Cl]H2O
  • Available nitric oxide was reduced by 42% at 100 μM. [0166]
    • EXAMPLE 6 K[Ru(H2edta)Cl2]H2O
  • Available nitric oxide was reduced by 77% at 100 μM test compound. [0167]
    • EXMAPLE 14 [Ru2(OAc)4]Cl
  • Available nitric oxide was reduced by 47% at 100 μM. [0168]
    • EXAMPLE 15 [Ru(NH3)5Cl]Cl2
  • Available nitric oxide was reduced by 86% at 100 μM test compound. [0169]
    • EXAMPLE 26 [Ru(maltolato)3]
  • Available nitric oxide was reduced by 71% at 100 μM. [0170]
    TABLE 1
    % Decrease of Available
    Nitric Oxide
    Example 1  25 μM 12
     50 μM 23
    100 μM 75
    Example 2 100 μM 82
    Example 3 100 μM 42
    Example 6 100 μM 77
    Example 14 100 μM 47
    Example 15 100 μM 86
    Example 26 100 μM 71
  • Ex-Vivo Tests [0171]
    • EXAMPLE 2
  • Application of test compound resulted in a dose-dependent vasoconstriction at 10 μM and 100 μM. This effect was reversible by washout with Krebs solution. [0172]
    • EXAMPLE 3
  • Application of test compound resulted in a dose-dependent vasoconstriction at 10 μM and 100 μM. This effect was reversible by washout with Krebs solution. [0173]
    • EXAMPLE 14
  • Application of test compound resulted in a dose-dependent vasoconstriction at 10 μM and 100 μM. This effect was reversible by washout with Krebs solution. [0174]
    • EXAMPLE 15
  • Application of test compound resulted in a dose-dependent vasoconstriction at 10 μM and 100 μM. This effect was reversible by washout with Krebs solution. [0175]
    • EXAMPLE 26
  • Application of test compound resulted in a dose-dependent vasoconstrietion at 10 μM and 100 μM and 1000 μM. This effect was reversible by washout with Krebs solution. [0176]
    TABLE 2
    % Vasoconstriction
    Example 2  10 μM 20
     100 μM 69
    Example 3  10 μM 17
     100 μM 59
    Example 14  10 μM 11
     100 μM 40
    Example 15  10 μM 16
     100 μM 86
    Example 26  10 μM 10
     100 μM 18
    1000 μM 25

Claims (29)

1. The use of a neutral, anionic or cationic metal complex having at least one site for coordination with NO, of formula
[Ma(XbL)cYdZe]a±  formula I,
in the manufacture of a medicament for the attenuation of NO levels where NO in implicated in disease,
where:
M is a metal ion or a mixture of metal ions;
X is a cation or a mixture of cations;
L is a ligand, or mixture of ligands each containing at least two different donor atoms selected from the elements of Group IV, Group V or Group VI of the Periodic Table;
Y is a ligand, or a mixture of the same or different ligands each containing at least one donor atom or more than one donor atom, which donor atom is selected from the elements of Group IV, Group V or Group VI of the Periodic Table;
and
Z is a halide or pseudohalide ion or a mixture of halide ions and pseudohalide ions;
a=1-3; b=0-12; c=0-18; d=0-18; e=0-18; and n=0-10;
provided that at least one of c, d and e is 1 or more;
and where c is 0; b is also 0;
and where a is 1; c, d and e are not greater than 9;
and where a is 2; c, d and e are not greater than 12.
2. The use of a complex of formula I in the manufacture of a medicament for the treatment of NO-overproduction related disease.
3. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 1, wherein M is a first, second or third row transition metal ion.
4. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 1, wherein M is an Rh, Ru, Os, Mn, Co, Cr or Re ion.
5. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 4, wherein M is an Rh, Ru or Os ion.
6. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 5, wherein M is in oxidation state III.
7. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to any of claims 1-6, wherein X is a mono-, di- or tri-valent cation.
8. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 7, wherein X is H+, K+, Na+, NH4 + or Ca2+.
9. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to any of claims 1-8, wherein L is a ligand containing both nitrogen and oxygen donor atoms.
10. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 9, wherein L is edda, edta, nta, dipic, pic, dtpa, hedtra, tedta or dtedta.
11. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to any of claims 1-10, wherein Y is a ligand containing at least one of N, O, S, C or P donor groups.
12. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 11, wherein said N donor group is ammine, amine, amide, nitrile or nitride or derivatives thereof.
13. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 11, wherein said O donor group is carboxylic acid, ester or derivatives thereof, water, oxide, sulphoxide, hydroxide, acetate, lactate, propionate, oxalate or maltolate.
14. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 11, wherein said S donor group is sulphoxide, dialkylsulphide, dialkylcarbamate, dithiocarbamate, or dithiophosphate.
15. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 11, wherein said C donor group is carbon monoxide or isocyanide.
16. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 11, wherein said P donor group is trialkylphosphine.
17. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to any preceding claim, wherein Z is a halide.
18. The use of a complex of formula I in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease, according to claim 17, wherein Z is chloride.
19. The use of an optionally hydrated ruthenium complex of formula
[Ru(H0-6L″)1-3Y0-2Cl1-4](0-4)±  formula II,
where L″ is an amide or ester or derivative thereof, or a polydentate aminocarboxylate ligand, for example edda, tropolone edta, nta, dipic, pic, dtpa, hedtra, tedta or dtedta or a mixture of any of these, and Y is as defined above and may for example be selected from acetylacetone (acac), a β-diketonate, water, dimethylsulphoxide (dmso), carboxylate, bidentate carboxylate, catechol, kojic acid, maltol, hydroxide, tropolone, malonic acid, oxalic acid, 2,3-dihydroxynaphthalene, squaric acid, acetate, a sulphate and a glycolate in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease.
20. A pharmaceutical composition containing an optionally hydrated complex of formula
[M1-3Y1-18Cl0-18](0-6)±  formula III
wherein Y is a sulphur donor ligand.
21. The use of an optionally hydrated complex of ruthenium of formula
[M′″1-3Y′″1-18Cl0-18](0-6)±  formula III
where M′″ is ruthenium and Y′″ is an oxygen-donor ligand such as acetate, lactate, water, oxide, propionate, oxalate or mialtolate or a combination of these, in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease.
22. The use of an optionally hydrated complex of ruthenium of formula
[RuYIV 1-9Cl1-9](0-4)±  formula IV
where YIV is a nitrogen-donor ligand such as ammine, ethylenediamine (en), pyridine (py), 1,10-phenanthroline (phen), 2,2′-bipyridine (bipy), 1,4,8,11=tetraaza-cyclotetradecane (cyclam), 2,3,7,8,12,13,17,18-octaethylporphyrin (oep) or a combination of these, in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease.
23. The use of an optionally hydrated complex of ruthenium or osmium of general formula
[M1-3Y1-18Cl0-18](0-6)±  formula V
where Y is a combination according to claims 19, 20, 21, or 22 in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease.
24. The use of an optionally hydrated complex of general formula
[M1-3Y1-18Cl0-18](0-6)±
where Y is a sulphur donor ligand, in the manufacture of a medicament for the attenuation of NO levels where NO is implicated in disease.
25. A pharmaceutical composition containing an optionally hydrated ruthenium complex as described in claim 19.
26. A pharmaceutical composition containing an optionally hydrated complex of ruthenium as described in claim 21, wherein Y′″ is an oxygen donor ligand selected from the group acetate, lactate, oxide, propionate and maltolate.
27. A pharmaceutical composition containing an optionally hydrated complex of ruthenium as described in claim 22, wherein YIV is a nitrogen donor ligand selected from the group en, py, phen, bipy, cyclam or oep.
28. A pharmaceutical composition containing an optionally hydrated complex of formula
[Os(ox)(bipy)2]
29. A pharmaceutical composition containing an optionally hydrated complex of formula
[Ru(acac)2(MeCN)2]+
US09/802,523 1993-08-25 2001-03-09 Pharmaceutical compositions comprising metal complexes Expired - Fee Related US6417182B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/802,523 US6417182B1 (en) 1993-08-25 2001-03-09 Pharmaceutical compositions comprising metal complexes
US10/017,764 US20020193363A1 (en) 1996-02-26 2001-12-07 Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
GB93/17686.5 1993-08-25
GB9317686 1993-08-25
GB939317686A GB9317686D0 (en) 1993-08-25 1993-08-25 Pharmaceutical compositions
WOPCT/GB94/01817 1994-08-19
PCT/GB1994/001817 WO1995005814A1 (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
US08/602,814 US5824673A (en) 1993-08-25 1994-08-19 Pharmaceutical compositions comprising metal complexes
US09/175,028 US6284752B1 (en) 1993-08-25 1998-10-19 Pharmaceutical compositions comprising metal complexes
US09/802,523 US6417182B1 (en) 1993-08-25 2001-03-09 Pharmaceutical compositions comprising metal complexes

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/175,028 Continuation US6284752B1 (en) 1993-08-25 1998-10-19 Pharmaceutical compositions comprising metal complexes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/017,764 Continuation-In-Part US20020193363A1 (en) 1996-02-26 2001-12-07 Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity

Publications (2)

Publication Number Publication Date
US20020045611A1 true US20020045611A1 (en) 2002-04-18
US6417182B1 US6417182B1 (en) 2002-07-09

Family

ID=27266826

Family Applications (1)

Application Number Title Priority Date Filing Date
US09/802,523 Expired - Fee Related US6417182B1 (en) 1993-08-25 2001-03-09 Pharmaceutical compositions comprising metal complexes

Country Status (1)

Country Link
US (1) US6417182B1 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134450A1 (en) * 2002-01-09 2003-07-17 Lee Teck Kheng Elimination of RDL using tape base flip chip on flex for die stacking
US20030164541A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Method and apparatus for dielectric filling of flip chip on interposer assembly
US20030166312A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Methods for assembly and packaging of flip chip configured dice with interposer
US20030164551A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Method and apparatus for flip-chip packaging providing testing capability
US20030164540A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Semiconductor die packages with recessed interconnecting structures and methods for assembling the same
US20030164548A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Flip chip packaging using recessed interposer terminals
US20040036170A1 (en) * 2002-08-20 2004-02-26 Lee Teck Kheng Double bumping of flexible substrate for first and second level interconnects
US20040224437A1 (en) * 2001-08-21 2004-11-11 Micron Technology, Inc. Microelectronic devices including underfill apertures
US20050025805A1 (en) * 2003-07-28 2005-02-03 Adam Heller Osmium compounds for reduction of adverse inflammation
US20050059064A1 (en) * 2003-08-28 2005-03-17 Ursula Obst Oligonucleotide, method and system for detecting antibiotic resistance-mediating genes in microorganisms by means of real-time PCR
US20060115542A1 (en) * 2001-05-15 2006-06-01 Motterlini Roberto A Therapeutic delivery of carbon monoxide
US20060127501A1 (en) * 2002-11-20 2006-06-15 Motterlini Roberto A Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20060142621A1 (en) * 2003-01-29 2006-06-29 Tiekink Edward R T Bismuth dithiocarbamate compounds and uses thereof
US20060175690A1 (en) * 2002-03-04 2006-08-10 Lee Teck K Interposer configured to reduce the profiles of semiconductor device assemblies, packages including the same, and methods
US7964220B2 (en) 2002-02-04 2011-06-21 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US8389572B2 (en) 2006-01-24 2013-03-05 Hemocorm Limited Therapeutic delivery of carbon monoxide
US9062089B2 (en) 2011-07-21 2015-06-23 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
AU737650B2 (en) 1997-11-03 2001-08-23 Duke University Substituted porphyrins
NZ513164A (en) * 1999-01-25 2006-03-31 Nat Jewish Med & Res Center Substituted porphyrins
US20030032634A1 (en) * 2001-06-01 2003-02-13 Piganelli Jon D. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
US20030069281A1 (en) * 2000-06-14 2003-04-10 Irwin Fridovich Tetrapyrroles
DE60233317D1 (en) * 2001-01-19 2009-09-24 Nat Jewish Med & Res Center MEDICAMENT FOR PROTECTION IN RADIO THERAPY
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
US7485721B2 (en) * 2002-06-07 2009-02-03 Duke University Substituted porphyrins
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
ES2464728T3 (en) 2008-05-23 2014-06-03 National Jewish Health Compounds for use in the treatment of lesions associated with exposure to an alkylating chemical species
WO2012138988A2 (en) * 2011-04-07 2012-10-11 The Research Foundation Of The City University Of New York Organometallic anti-cancer complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157032A (en) 1985-01-18 1992-10-20 The Trustees Of Columbia University In The City Of New York Mixed ligand complexes and uses thereof as binding agents and probes to DNA
DK63490D0 (en) 1990-03-09 1990-03-09 Novo Nordisk As METHOD OF PRODUCING CHEESE
GB9317686D0 (en) * 1993-08-25 1993-10-13 Johnson Matthey Plc Pharmaceutical compositions

Cited By (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060115542A1 (en) * 2001-05-15 2006-06-01 Motterlini Roberto A Therapeutic delivery of carbon monoxide
US8236339B2 (en) 2001-05-15 2012-08-07 Hemocorm Limited Therapeutic delivery of carbon monoxide
US20060267171A1 (en) * 2001-08-21 2006-11-30 Micron Technology, Inc. Semiconductor device modules, semiconductor devices, and microelectronic devices
US20040224437A1 (en) * 2001-08-21 2004-11-11 Micron Technology, Inc. Microelectronic devices including underfill apertures
US8441113B2 (en) 2002-01-09 2013-05-14 Micron Technology, Inc. Elimination of RDL using tape base flip chip on flex for die stacking
US8125065B2 (en) 2002-01-09 2012-02-28 Micron Technology, Inc. Elimination of RDL using tape base flip chip on flex for die stacking
US20030134450A1 (en) * 2002-01-09 2003-07-17 Lee Teck Kheng Elimination of RDL using tape base flip chip on flex for die stacking
US9023402B2 (en) 2002-02-04 2015-05-05 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US20110237546A1 (en) * 2002-02-04 2011-09-29 Werner Haas Method for treating a mammal by administration of a compound having the ability to release co
US7964220B2 (en) 2002-02-04 2011-06-21 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Method for treating a mammal by administration of a compound having the ability to release CO
US20040197955A1 (en) * 2002-03-04 2004-10-07 Lee Teck Kheng Methods for assembly and packaging of flip chip configured dice with interposer
US8269326B2 (en) 2002-03-04 2012-09-18 Micron Technology, Inc. Semiconductor device assemblies
US20030164541A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Method and apparatus for dielectric filling of flip chip on interposer assembly
US20030166312A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Methods for assembly and packaging of flip chip configured dice with interposer
US20030164551A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Method and apparatus for flip-chip packaging providing testing capability
US20060175690A1 (en) * 2002-03-04 2006-08-10 Lee Teck K Interposer configured to reduce the profiles of semiconductor device assemblies, packages including the same, and methods
US20060240595A1 (en) * 2002-03-04 2006-10-26 Lee Teck K Method and apparatus for flip-chip packaging providing testing capability
US20030164540A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Semiconductor die packages with recessed interconnecting structures and methods for assembling the same
US7161237B2 (en) * 2002-03-04 2007-01-09 Micron Technology, Inc. Flip chip packaging using recessed interposer terminals
US7902648B2 (en) 2002-03-04 2011-03-08 Micron Technology, Inc. Interposer configured to reduce the profiles of semiconductor device assemblies, packages including the same, and methods
US7915718B2 (en) 2002-03-04 2011-03-29 Micron Technology, Inc. Apparatus for flip-chip packaging providing testing capability
US20030164548A1 (en) * 2002-03-04 2003-09-04 Lee Teck Kheng Flip chip packaging using recessed interposer terminals
US20040036170A1 (en) * 2002-08-20 2004-02-26 Lee Teck Kheng Double bumping of flexible substrate for first and second level interconnects
US20040198033A1 (en) * 2002-08-20 2004-10-07 Lee Teck Kheng Double bumping of flexible substrate for first and second level interconnects
US7989650B2 (en) 2002-11-20 2011-08-02 Hemocorm Limited Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20060127501A1 (en) * 2002-11-20 2006-06-15 Motterlini Roberto A Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
US20060142621A1 (en) * 2003-01-29 2006-06-29 Tiekink Edward R T Bismuth dithiocarbamate compounds and uses thereof
US20050025805A1 (en) * 2003-07-28 2005-02-03 Adam Heller Osmium compounds for reduction of adverse inflammation
US20050059064A1 (en) * 2003-08-28 2005-03-17 Ursula Obst Oligonucleotide, method and system for detecting antibiotic resistance-mediating genes in microorganisms by means of real-time PCR
US8389572B2 (en) 2006-01-24 2013-03-05 Hemocorm Limited Therapeutic delivery of carbon monoxide
US9163044B2 (en) 2011-04-19 2015-10-20 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
US9062089B2 (en) 2011-07-21 2015-06-23 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof
US9611286B2 (en) 2011-07-21 2017-04-04 Alfama, Inc. Ruthenium carbon monoxide releasing molecules and uses thereof

Also Published As

Publication number Publication date
US6417182B1 (en) 2002-07-09

Similar Documents

Publication Publication Date Title
US6417182B1 (en) Pharmaceutical compositions comprising metal complexes
US5824673A (en) Pharmaceutical compositions comprising metal complexes
US6284752B1 (en) Pharmaceutical compositions comprising metal complexes
US20020049190A1 (en) Pharmaceutical compositions comprising metal complexes
Tshuva et al. Modern cytotoxic titanium (IV) complexes; Insights on the enigmatic involvement of hydrolysis
Wang et al. Syntheses and evaluation of drug-like properties of CO-releasing molecules containing ruthenium and group 6 metal
Tsubomura et al. Highly active antitumor platinum (II) complexes of amino sugars
US20020193363A1 (en) Use of nitric oxide scavengers to modulate inflammation and matrix metalloproteinase activity
JPS595599B2 (en) Platinum organic complex, method for producing the same, and therapeutic agent for malignant tumor comprising the complex
CN101469004B (en) Platinum complexes
Rosowsky et al. Methotrexate analogs. 19. Replacement of the glutamate side-chain in classical antifolates by L-homocysteic acid and L-cysteic acid: effect on enzyme inhibition and antitumor activity
CA2022311A1 (en) Copper radiosensitizers
CN105713047A (en) Platinum (II) coordination complex and preparing method and application thereof
US9585861B1 (en) Method for treating a cancer with a mixed ligand gold(III) complexes as anti-cancer agents
CN114907417A (en) Tetravalent platinum ternary complex containing artesunate and non-steroidal anti-inflammatory drug and preparation method and application thereof
CA2552916A1 (en) Metal complexes having vitamin b12 as a ligand
Abuhijleh et al. Characterization and catecholase-mimetic behavior of imidazole adducts of copper (II) valproate. Crystal structure of the 2-methylimidazole adduct
He et al. Antitumor activity of iridium/ruthenium complexes containing nitro-substituted quinoline ligands in vivo and in vitro
Brubaker et al. Mixed-ligand complexes of cobalt (III). Chelated (amino acid)(tetramine) cobalt (III) complexes
Berners-Price et al. [Ag (I)(Et 2 PCH 2 CH 2 PPh 2) 2] NO 3: An Antimitochondrial Silver Complex
JP2016520538A (en) Fe (III) complexes for the treatment and prevention of iron deficiency and iron deficiency anemia
CN108484661A (en) One kind six vanadic acid-Beta-alanine tert-butyl ester derivative and the preparation method and application thereof
Meiske et al. Synthesis and spectral characterization of the mixed-ligand complexes [N-(2-pyridylmethyl)-L-aspartato][amino acidato] cobalt (III), Co (PLASP)(AA)
Guk et al. Conjugates of titanocene with non-steroidal anti-inflammatory drugs: synthesis, unusual NMR characteristics, stability and cytotoxicity
CN115286662A (en) Amino acid hybridized tetranuclear platinum complex, preparation method and application

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 4

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20100709